Patents by Inventor Frank Sieg
Frank Sieg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220280605Abstract: Use of a peptide or fragment thereof comprising SEQ ID NO. 1, or a peptide or fragment having at least 80% sequence identity thereto, in the manufacture of a medicament for one or more of reducing triglycerides, reducing LDL, reducing sdLDL, reducing glucose, reducing insulin, reducing HbA1c and increasing insulin sensitivity.Type: ApplicationFiled: April 29, 2020Publication date: September 8, 2022Inventors: Denis Watson, Christopher McMahon, Blake Paget, David Norrie, Kim Whiteman, Frank Sieg
-
Publication number: 20170218023Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: ApplicationFiled: April 13, 2017Publication date: August 3, 2017Inventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
Patent number: 9650418Abstract: Embodiments of this invention include synthetic compounds (NRP analogs) of peptides termed neural regeneration peptides (NRPs). NRP analogs are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogs can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: GrantFiled: May 1, 2015Date of Patent: May 16, 2017Assignee: CURONZ HOLDINGS COMPANY LIMITEDInventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
METHOD OF TREATING OR PREVENTING EPILEPSY OR SEIZURES USING ONE OR MORE NEURAL REGENERATION PEPTIDES
Publication number: 20160296590Abstract: The invention relates to a method of treating or preventing epilepsy or seizures or damage caused therefrom in a subject using one or more neural regeneration peptides (NRPs). In particular, the invention relates to the use of NRP 2945 and closely related analogues for treating or preventing epilepsy or seizures in a subject.Type: ApplicationFiled: December 4, 2014Publication date: October 13, 2016Inventor: Frank SIEG -
Publication number: 20160031937Abstract: This invention relates to neural regeneration peptides (NRPs), including NRP-2945, NRP-2983 and NNZ-4921, as well as the receptors that have been newly identified as interacting with these NRPs, such as CXCR4 in collaboration with CCR3. The invention further relates to methods of using these NRPs and its respective chemokine receptors, as well as compositions comprising such components.Type: ApplicationFiled: March 7, 2014Publication date: February 4, 2016Inventor: Frank SIEG
-
Publication number: 20160015771Abstract: The invention relates to a method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury including the step of administering an effective amount of a peptide comprising the sequence: GlyArgArgAlaAlaProGlyArgAibGlyGly (SEQ ID NO:1) or the sequence GlyArgArgAlaAlaProGlyArgAibGlyGly-HN2 (SEQ ID NO:2) to a subject in need thereof.Type: ApplicationFiled: July 26, 2013Publication date: January 21, 2016Applicant: Curonz Holdings Company LimitedInventor: Frank SIEG
-
Publication number: 20150307553Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: ApplicationFiled: May 1, 2015Publication date: October 29, 2015Inventors: Paul William Richard Harris, Margaret Ann Brimble, Frank Sieg
-
Patent number: 9040485Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizaing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: GrantFiled: October 15, 2012Date of Patent: May 26, 2015Assignee: CURONZ HOLDINGS COMPANY LIMITEDInventors: Paul William Richard Harris, Margaret Ann Brimble, Frank Sieg
-
Publication number: 20130231289Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizaing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: ApplicationFiled: October 15, 2012Publication date: September 5, 2013Applicant: Curonz Holdings Company LimitedInventors: Paul William Richard Harris, Margaret Ann Brimble, Frank Sieg
-
Patent number: 8309684Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: GrantFiled: April 6, 2010Date of Patent: November 13, 2012Assignee: Curonz Holdings Company LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
Patent number: 8138304Abstract: Neural regeneration peptide consisting of a sequence comprised in the sequence of REGRRAAPGRAGG(SEQ ID NO:1).Type: GrantFiled: May 5, 2006Date of Patent: March 20, 2012Assignee: Neuren Pharmaceuticals LimitedInventors: Frank Sieg, Margaret Anne Brimble, Victoria Justine Muir
-
Publication number: 20110306557Abstract: The invention discloses a family of neuronal migration-inducing, proliferation-promoting and neurite outgrowth promoting factors, termed NRP compounds, and provides compositions and methods for the use of NRP compounds in the treatment of brain injury and neurodegenerative disease. NRP-1 compounds induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient.Type: ApplicationFiled: August 3, 2010Publication date: December 15, 2011Applicant: Curonz Holdings Company LimitedInventors: Frank Sieg, Paul Hughes
-
Patent number: 8067425Abstract: Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterized by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.Type: GrantFiled: August 31, 2004Date of Patent: November 29, 2011Assignee: Neuren Pharmaceuticals LimitedInventors: Margaret Anne Brimble, Jian Guan, Frank Sieg
-
Publication number: 20110098228Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: ApplicationFiled: April 6, 2010Publication date: April 28, 2011Applicant: Neuren Pharmaceuticals LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
Patent number: 7863304Abstract: Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease.Type: GrantFiled: November 20, 2007Date of Patent: January 4, 2011Assignee: Neuren Pharmaceuticals LimitedInventors: Margaret Anne Brimble, Paul William Richard Harris, Frank Sieg
-
Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
Patent number: 7767786Abstract: The invention discloses a family of neuronal migration-inducing, proliferation-promoting and neurite outgrowth promoting factors, termed NRP compounds, and provides compositions and methods for the use of NRP compounds in the treatment of brain injury and neurodegenerative disease. NRP compounds induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient.Type: GrantFiled: August 22, 2002Date of Patent: August 3, 2010Assignee: Neuren Pharmaceuticals Ltd.Inventors: Frank Sieg, Paul Hughes -
Publication number: 20100130410Abstract: Embodiments of this invention include novel peptides that can promote survival of neurons and other cell types. Other embodiments of this invention include the methods for the use of peptides to promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation, neuronal survival and/or trophoblast proliferation, trophoblast migration and trophoblase survival. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly or indirectly via a replicable vehicle. NRP compounds can be formulated into pharmaceutically acceptable dosage forms for therapeutic use. Kits containing pre-determined doses of an NRP can be used to conveniently store, prepare and administer an NRP to a subject in need thereof.Type: ApplicationFiled: May 5, 2006Publication date: May 27, 2010Applicant: Neuren Pharmaceuticals LimitedInventors: Frank Sieg, Margaret Anne Brimble, Victoria Justine Muir
-
Patent number: 7605177Abstract: This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.Type: GrantFiled: December 20, 2005Date of Patent: October 20, 2009Assignee: Neuren Pharmaceuticals LimitedInventors: Peter David Gluckman, Gregory Brian Thomas, Jian Guan, Michael Dragunow, Ashmit Kumar Anand, Frank Sieg, Margaret Anne Brimble
-
Patent number: 7563862Abstract: The invention discloses a family of peptides termed NRP compounds or NRPs that can promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation and/or neuronal survival, and provides compositions and methods for the use of NRPs in the treatment of brain injury and neurodegenerative disease. NRP compounds can induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as exposure to toxins, stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. NRP compounds can be formulated into pharmaceutically acceptable dose forms for therapeutic use.Type: GrantFiled: October 29, 2004Date of Patent: July 21, 2009Assignee: Neuren Pharmaceuticals LimitedInventors: Frank Sieg, Paul Edmund Hughes, Thorsten Gorba
-
Publication number: 20080145335Abstract: Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease.Type: ApplicationFiled: November 20, 2007Publication date: June 19, 2008Applicant: Neuren Pharmaceuticals LimitedInventors: Margaret Anne Brimble, Paul William Richard Harris, Frank Sieg